Document Detail


Adenosine transport, erythrocyte deformability and microvascular dysfunction: an unrecognized potential role for dipyridamole therapy.
MedLine Citation:
PMID:  20364065     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Reperfusion injury and no-reflow phenomenon are known entities that contribute to persistent impairment in myocardial perfusion and regional myocardial dysfunction following restoration of epicardial coronary blood flow after a myocardial infarction. Following prolonged ischemia, oxidative stress and inflammation-mediated alterations in erythrocyte mechanics and microvascular architecture play a major role in ischemia/reperfusion injury and no-reflow phenomenon. An increase in red cell rigidity is an important rheological aspect of RBCs, which facilitates platelet aggregation with the subendothelium. Dipyridamole inhibits the reuptake of adenosine which causes platelet inhibition and vasodilatation. Dipyridamole improves microvascular function by increasing RBC deformability and reducing blood viscosity. In addition, it has anti-oxidant and anti-inflammatory properties that provide protection to the microvasculature. This review discusses the potential role for dipyridamole therapy in the treatment of microvascular dysfunction.
Authors:
Jignesh Bhavsar; Robert S Rosenson
Related Documents :
19855945 - Mitochondrial involvement in cardiac apoptosis during ischemia and reperfusion: can we ...
16352265 - The aging myocardium: roles of mitochondrial damage and lysosomal degradation.
1336665 - Does the antiarrhythmic effect of dmpo originate from its oxygen radical trapping prope...
22417735 - Cardiomyocyte size estimated from noninvasive measurements of left ventricular wall thi...
12914865 - Frequency, determinants, and clinical implications of residual intracoronary thrombus f...
18220015 - Silent infarction in patients with first-ever stroke.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Clinical hemorheology and microcirculation     Volume:  44     ISSN:  1875-8622     ISO Abbreviation:  Clin. Hemorheol. Microcirc.     Publication Date:  2010  
Date Detail:
Created Date:  2010-04-05     Completed Date:  2010-09-20     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9709206     Medline TA:  Clin Hemorheol Microcirc     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  193-205     Citation Subset:  IM    
Affiliation:
Division of Cardiovascular Medicine, University of Michigan, Ann Arbor, MI, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adenosine / pharmacokinetics*,  therapeutic use
Blood Viscosity / drug effects
Dipyridamole / pharmacology*,  therapeutic use
Erythrocyte Deformability / drug effects,  physiology*
Erythrocytes / drug effects*,  physiology
Humans
Myocardial Infarction / blood,  drug therapy*
Myocardial Reperfusion Injury / blood,  drug therapy*
Chemical
Reg. No./Substance:
58-32-2/Dipyridamole; 58-61-7/Adenosine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Relationship between C-reactive protein and early activation of leukocytes indicated by leukocyte an...
Next Document:  Acute dichlorvos poisoning induces hemorheological abnormalities in rabbits via oxidative stress.